The global next generation Sequencing market size is expected to reach USD 42.25 billion by 2033, registering a CAGR of 18.00% from 2026 to 2033, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.
Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.
Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.
The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.
Request a free sample copy or view the report summary: Next Generation Sequencing Market Report
The consumables segment accounted for the largest market revenue share in 2025 and is expected to grow at the fastest CAGR from 2026 to 2033
The targeted sequencing and resequencing segment led the market with the largest revenue share of 48.32% in 2025
The oncology segment led the market with the largest revenue share of 31.97% in 2025, driven by the essential role of genomic data analysis in cancer research, diagnostics, and targeted therapies.
The sequencing segment led the market with the largest revenue share of 64.31% in 2025 and is expected to grow at the fastest CAGR over the forecast period
The academic research segment led the market with the largest revenue share of 36.05% in 2025. The application of NGS solutions in research projects conducted at universities and research centers accounts for the largest share of this segment in the market.
North America dominated the global next-generation sequencing market with the largest revenue share of 44.78% in 2025
Grand View Research has segmented the global next-generation sequencing market report based on the technology, product, workflow, end use, and region:
Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2021 - 2033)
WGS
Whole Exome Sequencing
Targeted Sequencing & Resequencing
DNA-based
RNA-based
Others
Next Generation Sequencing Product Outlook (Revenue, USD Million, 2021 - 2033)
Platform
Sequencing
Data Analysis
Consumables
Sample Preparation
Target Enrichment
Others
Next Generation Sequencing Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Diagnostics and Screening
Oncology Screening
Sporadic Cancer
Inherited Cancer
Companion Diagnostics
Other Diagnostics
Research Studies
Clinical Investigation
Infectious Diseases
Inherited Diseases
Idiopathic Diseases
Non-Communicable/Other Diseases
Reproductive Health
NIPT
Aneuploidy
Microdeletions
PGT
Newborn Genetic Screening
Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Consumer Genomics
Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2021 - 2033)
Pre-Sequencing
Nucleic Acid Extraction
Library Preparation
Sequencing
NGS Data Analysis
NGS Primary Data Analysis
NGS Secondary Data Analysis
NGS Tertiary Data Analysis
Next Generation Sequencing End Use Outlook (Revenue, USD Million, 2021 - 2033)
Academic Research
Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Other Users
Next Generation Sequencing Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Next Generation Sequencing Market
Illumina
F. Hoffman-La Roche Ltd.
QIAGEN
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
PacBio
Oxford Nanopore Technologies
Revvity, Inc.
Merck KGaA
BGI
"The quality of research they have done for us has been excellent..."